¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2024³â Á¦2ȸ ´ëÇѼҾƺñ´¢ÀÇÇÐȸ Transitional Urology Symposium : 2024-06-29

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2024³â Á¦2ȸ ´ëÇѼҾƺñ´¢ÀÇÇÐȸ Transitional Urology Symposium : 2024-06-29
±³À°ÀÏÀÚ : 2024-06-29
±³À°Àå¼Ò : ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë

±³À°ÁÖÁ¦ : 2024³â Á¦2ȸ ´ëÇѼҾƺñ´¢ÀÇÇÐȸ Transitional Urology Symposium

ÁÖÃÖ±â°ü : ´ëÇѺñ´¢ÀÇÇÐȸ(19.2 ¸íĪº¯°æ ´ëÇѺñ´¢±â°úÇÐȸ)
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѼҾƺñ´¢ÀÇÇÐȸ

´ã´çÀÚ : À̼¼Èñ
¿¬¶ôó : 02-573-8190

À̸ÞÀÏ : urology@urology.or.kr

±³À°Á¾·ù : ºñ´¢ÀÇÇаú

Âü¼®¿¹»óÀÎ : 50¸í
Èñ¸ÁÆòÁ¡ : 2Á¡

Áö¿ª : ºÎ»ê±¤¿ª½Ã
±³À°½Ã°£ : 3 ½Ã°£ 10ºÐ

¼¼ºÎ¼ö°­·á : 22,000¿ø  

ºñ°í ȸºñ ³³ºÎ¿¡ µû¶ó Â÷µî ºÎ°úÇÒ ¼ö ÀÖÀ½


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 09:00~09:30 Enuresis and nocturia in an adolescence ±è¼ºÃ¶, °íÇõÁØ(¿ï»êÀÇ´ë, µ¿¾ÆÀÇ´ë)

±³À°½Ã°£ 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 09:30~10:00 Overactive bladder and urinary incontinence symptoms in an adolescence ÀÓ¿µÀç, ±èµ¿¼ö(¼­¿ïÀÇ´ë, °æÈñÀÇ´ë)

Åä·Ð 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 10:00~10:30 Panel discussion ()

ÈÞ½Ä 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 10:30~10:50 Break ()

±³À°½Ã°£ 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 10:50~11:10 Management of ureterocele ÇÏÁö¿ë(°è¸íÀÇ´ë)

±³À°½Ã°£ 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 11:10~11:30 Management of ureteropelvic junction obstruction (UPJO) ¹èÀçÇö(°í·ÁÀÇ´ë)

Åä·Ð 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 11:30~12:00 Panel discussion ()

±³À°½Ã°£ 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 12:00~12:15 Clinical Utility of Low-dose ¥â3-Adrenoreceptor Agonists, Mirabegron, for the Treatment of Overactive Bladder : In children(KSPU) ¼Û»óÈÆ(¿ï»êÀÇ´ë)

±³À°½Ã°£ 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 12:15~12:30 Clinical Utility of Low-dose ¥â3-Adrenoreceptor Agonists, Mirabegron, for the Treatment of Overactive Bladder : In adult(KCS) ¹èÈ£¿µ(¿ï»êÀÇ´ë)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2024³â Á¦2ȸ ´ëÇѼҾƺñ´¢ÀÇÇÐȸ Transitional Urology Symposium : 2024-06-29""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û Á¦12ȸ ÀÎÁ¦ÀÇ´ë ÀÏ»ê¹éº´¿ø ½Å°æ¿Ü°ú ¿¬¼ö°­Á : 2024-06-29
´ÙÀ½±Û 2024³â ´ëÇѳëÀνŰæÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-29
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21168 ¼­¿ï ´ëÇÑ»çȸÁ¤½ÅÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-07-19 0 2 16:36:01
21167 ±¤ÁÖ ´ëÇÑ°íÇ÷¾ÐÇÐȸ Á¦85ȸ ±¤ÁÖ °³¿øÀÇ ¹× Àü°øÀÇ ¿¬¼ö°­Á : 2024-07-19 0 2 16:34:39
21166 ¼­¿ï (¿Â¶óÀÎ) ÀÇ·á±â°ü Á¾»çÀÚ ´ë»ó ¿¬¸íÀÇ·á°áÁ¤Á¦µµ ±âº»±³À° : 2024-07-19 0 2 16:33:34
21165 ¼­¿ï (¿Â¶óÀÎ) ÀÇ·á±â°ü Á¾»çÀÚ(ÀÇ·áÀÎ) ´ë»ó ¿¬¸íÀÇ·á°áÁ¤Á¦µµ ½ÉÈ­±³À° : 2024-07-19 0 2 16:32:05
21164 ÀüºÏ ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ È£³²Áöȸ - Á¦299Â÷ ¿ù·ÊÁý´ãȸ : 2024-07-19 0 0 16:30:42
21163 ºÎ»ê ´ëÇÑÀçÈ°ÀÇÇÐȸ Á¦164Â÷ ºÎ»ê¿ï»ê°æ³²Áöȸ Áý´ãȸ : 2024-07-18 0 0 16:29:06
21162 °æ±â ´ëÇÑÀ̺ñÀÎÈÄ°úÀÇ»çȸ 2024 Áöȸ½ÉÆ÷Áö¾ö-°æÀÎ(³²ºÎ) : 2024-07-16 0 0 16:25:42
21161 ¼­¿ï 2024³â 1Â÷ °í·Á´ëÇб³ ÀÇ°ú´ëÇÐ °¡Á¤ÀÇÇб³½Ç ¿¬¼ö°­Á : 2024-07-14 0 0 16:23:12
21160 ¼­¿ï 2024 Á¦16ȸ ´ëÇѼºÇü¿Ü°úÇÐȸ ´«¼ºÇü¿¬±¸È¸ Çмú½ÉÆ÷Áö¾ö : 2024-07-14 0 0 16:21:54
21159 ¼­¿ï Á¦11ȸ ´ëÇѺñ°úÇÐȸ ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-07-14 0 0 16:20:44
21158 ¼­¿ï °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ 2024³â ⸳62ÁÖ³â±â³ä ½ÉÆ÷Áö¾ö : 2024-07-13 0 0 16:19:06
21157 ¼­¿ï Á¦46ȸ Çѱ¹½ÉÃÊÀ½ÆÄÇÐȸ ¿öÅ©¼¥ : 2024-07-13 0 0 16:17:34
21156 °æ±â ºÐ´ç¼­¿ï´ëÇб³º´¿ø 24³â ´ëµ¿¸Æ ½ÉÆ÷Áö¿ò : 2024-07-13 0 0 16:15:18
21155 ¼­¿ï (¿Â¶óÀÎ) 2024³â ´ëÇѼҾÆû¼Ò³â°úÇÐȸ Á¦18Â÷ ÁöµµÀü¹®ÀÇ ±³À° : 2024-07-13 0 0 16:13:38
21154 ¼­¿ï 2024 ¿¬¼¼ÀÇ´ë Á¤Çü¿Ü°úÇб³½Ç ½ÉÆ÷Áö¿ò : ÃÖÁ¾Çõ ±³¼ö Á¤³â±â³ä : 2024-07-13 0 0 16:12:07
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷